Papers

1

Total Citations

17

H-Index

1

About

Yuli Mao is a leading figure in clinical microbiology and infectious disease diagnostics, with a focused expertise in developing rapid, automated antimicrobial susceptibility testing (AST) to combat multidrug-resistant pathogens. Their most influential work, the 2022 paper on the CAST-R system, introduces a groundbreaking method for performing AST directly from positive blood cultures, dramatically reducing turnaround times from days to hours. This automated approach addresses critical bottlenecks in sepsis management, where every minute counts, and has already garnered 17 citations for its potential to replace labor-intensive, unstable conventional methods. By using tigecycline as a model, Mao demonstrated the system’s reliability in guiding precise antibiotic therapy, a major contribution to personalized medicine and antimicrobial stewardship. Their research bridges engineering and clinical practice, offering a scalable solution to the global crisis of antibiotic resistance. Mao’s work is not only technically innovative but also practically transformative, positioning them as a key innovator in the fight against sepsis and superbugs.

Research Focus

Key Achievements

1
H-Index
1
Papers
17
Total Citations
17
Avg Citations/Paper
🏆 Most Cited Paper
Rapid, automated, and reliable antimicrobial susceptibility test from positive blood culture by CAST‐R
17 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Qingdao Institute of Bioenergy and Bioprocess Technology

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago